Clinical trials: Antiviral Treatment
HIV Infections
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients
The general aim is to evaluate the antiviral activity and safety of increasing doses of oral administered RTV-boosted BILR 355 BS (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day…
- Trial name
- NCT00294372
- Testing
- BILR 355 BS
- Where
- 11 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation
The main purposes of this study are: demonstrate the safety and efficacy of TPV/r among HCV or hepatitis B virus (HBV) co-infected HIV+population, three-class (NRTI, NNRTI, and PI) experienced, with documented resistance to more…
- Trial name
- NCT00447902
- Testing
- tipranavir, ritonavir
- Where
- 30 sites in United States, Argentina and 5 more
- Volunteers
- 11 people
- Sponsor
- Boehringer Ingelheim
COVID-19
Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection
Flonoltinib Maleate (FM) is a triple-target inhibitor of JAK2, FLT3, and CDK6. It inhibited JAK2 with an IC50 of 0.8 nM, whereas its IC50 values against JAK1, JAK3, and TYK2 were 690 nM, 557 nM, and 65 nM, respectively…
- Trial name
- NCT05713279
- Testing
- SOC
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Cytomegalovirus Retinitis, HIV Infections
A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
To determine the clinically safe and effective dose of intravitreal ISIS 2922 alone and as an additive antiviral therapy to ganciclovir in AIDS patients with cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00002156
- Testing
- Fomivirsen sodium, Ganciclovir
- Where
- 18 sites in United States
- Volunteers
- 194 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hepatitis B, HBV
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B e antigen (HBeAg)-negative subjects with chronic HBV infection.
- Conditions
- Hepatitis B, HBV, Hepatitis B, Chronic
- Trial name
- NCT04023721
- Testing
- Inarigivir soproxil, Nucleoside/nucleotide (NUC) analogue inhibitors
- Where
- 7 sites in Canada, United Kingdom
- Volunteers
- 64 people
- Sponsor
- F-star Therapeutics, Inc.
Infection, Human Immunodeficiency Virus
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
The purpose of this trial is to assess the antiviral activity and safety of a dolutegravir (DTG) containing regimen in HIV-1 infected, antiretroviral therapy (ART)-experienced adults with current or historical failure on an…
- Trial name
- VIKING-3 (NCT01328041)
- Testing
- dolutegravir
- Where
- 89 sites in United States, Belgium and 5 more
- Volunteers
- 183 people
- Sponsor
- ViiV Healthcare
HSV-2
Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2
The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes
- Trial name
- NCT01047540
- Testing
- AIC316
- Where
- 6 sites in United States
- Volunteers
- 156 people
- Sponsor
- AiCuris Anti-infective Cures AG
Chronic Hepatitis C
Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)
This study was to assess the safety and efficacy of sofosbuvir in combination with ribavirin (RBV) administered for 12 or 16 weeks in participants with genotypes 2 or 3 hepatitis C virus (HCV) infection as assessed by the…
- Trial name
- FUSION (NCT01604850)
- Testing
- SOF, RBV
- Where
- 67 sites in United States, Canada and 2 more
- Volunteers
- 202 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C, Hepatitis C (HCV)
ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients
This is a study of combination direct-acting antiviral agents (DAA) with or without ribavirin (RBV) in patients with chronic Hepatitis C Virus (HCV).
- Conditions
- Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
- Trial name
- NCT01464827
- Testing
- ABT-450, ABT-333, ABT-267
- Where
- 97 sites in United States, Australia and 7 more
- Volunteers
- 580 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C Virus Infection
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose combination (FDC) ± ribavirin (RBV) in participants with…
- Trial name
- NCT02536313
- Testing
- SOF/VEL/VOX, RBV
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Gilead Sciences
HIV Infections
A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past
To evaluate the safety and efficacy of high-dose lamivudine (3TC) alone versus zidovudine (AZT) alone versus 3TC at high and low doses in combination with AZT in HIV-1 infected patients.
- Trial name
- NCT00002320
- Testing
- Lamivudine, Zidovudine
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 320 people
- Sponsor
- Glaxo Wellcome
Viral Pneumonia
Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
The goal of this Phase 2 study is to assess the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection.
- Trial name
- INVENT (NCT06999603)
- Testing
- SNG001
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 11 people
- Sponsor
- Synairgen Research Ltd.
Hepatitis C, Chronic
Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)
The objective was to investigate the antiviral effect, safety, and pharmacokinetics of BI 201335 (Faldaprevir), given as a soft gelatine capsule, in patients with hepatitis C virus (HCV) genotype 1 infection.
- Trial name
- NCT00774397
- Testing
- BI 201335 NA 240 mg QD / LI, PegIFN/RBV, BI 201335 NA 120mg QD / LI
- Where
- 100 sites in United States, Argentina and 13 more
- Volunteers
- 719 people
- Sponsor
- Boehringer Ingelheim
Infection, Human Immunodeficiency Virus, HIV Infections
Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults
GSK2838232 is a novel HIV-1 maturation inhibitor (MI) that is being developed for the treatment of HIV-1 infection in combination with other antiretroviral therapy (ART).
- Trial name
- NCT03045861
- Testing
- GSK2838232, Cobicistat
- Where
- 14 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Hepatitis C Virus Infection
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection
The primary objective of the study is to evaluate the safety and tolerability of voxilaprevir (formerly GS-9857) alone or with sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) and antiviral activity of voxilaprevir…
- Trial name
- NCT02185794
- Testing
- Voxilaprevir, SOF/VEL
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 101 people
- Sponsor
- Gilead Sciences
Hepatitis C, HCV
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of ABT-450 with ritonavir (ABT-450/r) dosed in combination with ABT-072 and ribavirin (RBV) in treatment-naïve…
- Conditions
- Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
- Trial name
- NCT01221298
- Testing
- ABT-450, ABT-072, Ribavirin
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C, Chronic
Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
The purpose of this study was to evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with sovaprevir, ACH-0143102, and ribavirin (RBV) in genotype-1 (GT-1), treatment-naive, hepatitis C virus (HCV)…
- Trial name
- NCT01849562
- Testing
- Sovaprevir, ACH-3102, Ribavirin
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV Infections
Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir
The purpose of this study is to compare the effectiveness of giving indinavir plus efavirenz plus adefovir dipivoxil to patients who have failed treatment with nelfinavir and patients who have never taken a protease inhibitor…
- Trial name
- NCT00002220
- Testing
- Indinavir sulfate, Efavirenz, Levocarnitine
- Where
- 11 sites in United States
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis D, Chronic
A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
This randomized, single blind study will compare the antiviral effect of Pegasys (pegylated interferon alfa-2a) plus placebo versus Pegasys plus tenofovir in patients with chronic hepatitis D.
- Trial name
- NCT01088659
- Testing
- peginterferon alfa-2a [Pegasys], tenofovir
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients
This 2-arm study evaluated the efficacy and safety of Fuzeon with an integrase inhibitor in an expanded access program plus an optimized background antiviral regimen (AVR) in HIV-1 infected patients naive to Fuzeon and an…
- Trial name
- AMICI (NCT00488059)
- Testing
- enfuvirtide [Fuzeon], Optimized background ARV, Integrase inhibitor
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche